Compare · GH vs ILMN
GH vs ILMN
Side-by-side comparison of Guardant Health Inc. (GH) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GH and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.56B, about 1.5x GH ($16.66B).
- Over the past year, GH is up 153.5% and ILMN is up 91.0% - GH leads by 62.5 points.
- GH has been more active in the news (22 items in the past 4 weeks vs 21 for ILMN).
- Both have 25 recent analyst ratings on file.
- Company
- Guardant Health Inc.
- Illumina Inc.
- Price
- $125.57-5.55%
- $162.28-3.39%
- Market cap
- $16.66B
- $24.56B
- 1M return
- +36.16%
- +13.81%
- 1Y return
- +153.50%
- +90.96%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2000
- News (4w)
- 22
- 21
- Recent ratings
- 25
- 25
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest GH
- Director Krognes Steve E. sold $1,231,522 worth of shares (9,294 units at $132.51), decreasing direct ownership by 48% to 10,222 units (SEC Form 4)
- Goldman initiated coverage on Guardant Health with a new price target
- Director Joyce Meghan V. exercised 10,000 shares at a strike of $38.05 and sold $1,269,809 worth of shares (10,000 units at $126.98) (SEC Form 4)
- Wolfe Research resumed coverage on Guardant Health with a new price target
- Guardant Health upgraded by Evercore ISI with a new price target
- Director Krognes Steve E. converted options into 154 shares, increasing direct ownership by 0.80% to 19,516 units (SEC Form 4)
- Director Hidalgo Medina Manuel sold $130,060 worth of shares (1,000 units at $130.06), decreasing direct ownership by 61% to 639 units (SEC Form 4)
- Chief Legal Officer Saia John G. sold $1,250,836 worth of shares (10,000 units at $125.08), decreasing direct ownership by 22% to 35,950 units (SEC Form 4)
- Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
- American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
Latest ILMN
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director King David P was granted 2,072 shares (SEC Form 4)